88 related articles for article (PubMed ID: 20823157)
41. Novel perspectives on dendritic cell-based immunotherapy of cancer.
Bonaccorsi I; Pezzino G; Morandi B; Ferlazzo G
Immunol Lett; 2013; 155(1-2):6-10. PubMed ID: 24076312
[TBL] [Abstract][Full Text] [Related]
42. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
[TBL] [Abstract][Full Text] [Related]
43. Enhancement of anti-tumor immune responses by transfection of IFNγ gene into tumor using a novel type synthetic vector.
Wijesekera DP; Sugiura K; Yuba E; Ueda K; Wijewardana V; Kanegi R; Nishimura T; Ushigusa T; Hatoya S; Kono K; Inaba T
Vet Immunol Immunopathol; 2014 Nov; 162(1-2):59-64. PubMed ID: 25239100
[TBL] [Abstract][Full Text] [Related]
44. Why are dendritic cells central to cancer immunotherapy?
Colaco CA
Mol Med Today; 1999 Jan; 5(1):14-7. PubMed ID: 10088127
[TBL] [Abstract][Full Text] [Related]
45. Dendritic cells: development, function and potential use for cancer immunotherapy.
Avigan D
Blood Rev; 1999 Mar; 13(1):51-64. PubMed ID: 10225609
[TBL] [Abstract][Full Text] [Related]
46. Dendritic cells as adjuvants for immune-mediated resistance to tumors.
Schuler G; Steinman RM
J Exp Med; 1997 Oct; 186(8):1183-7. PubMed ID: 9379142
[No Abstract] [Full Text] [Related]
47. [Experimental tumor therapy using intratumoral injection of dendritic cells].
Kucera A; Skába R; Spísek R; Pajer P; Cervinková M
Rozhl Chir; 2009 Jul; 88(7):368-72. PubMed ID: 19750839
[TBL] [Abstract][Full Text] [Related]
48. [Significance of dendritic cells for the immunotherapy of tumors].
Weise JB; Maune S; Kabelitz D; Heiser A
HNO; 2005 Feb; 53(2):117-20. PubMed ID: 15657753
[No Abstract] [Full Text] [Related]
49. Cellular therapy.
Hersey P
Curr Opin Oncol; 1993 Nov; 5(6):1049-54. PubMed ID: 8305538
[TBL] [Abstract][Full Text] [Related]
50. Role of exosomes in immune regulation.
Li XB; Zhang ZR; Schluesener HJ; Xu SQ
J Cell Mol Med; 2006; 10(2):364-75. PubMed ID: 16796805
[TBL] [Abstract][Full Text] [Related]
51. Direct comparison of canine and human immune responses using transcriptomic and functional analyses.
Chow L; Wheat W; Ramirez D; Impastato R; Dow S
Sci Rep; 2024 Jan; 14(1):2207. PubMed ID: 38272935
[TBL] [Abstract][Full Text] [Related]
52. Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH; Verlingue L; de Miguel M; Pasanen A; Robbrecht D; Skytta T; Iivanainen S; Shetty S; Ma YT; Graham DM; Arora SP; Jaakkola P; Yap C; Xiang Y; Mandelin J; Karvonen MK; Jalkanen J; Karaman S; Koivunen JP; Minchom A; Hollmén M; Bono P
Cell Rep Med; 2023 Dec; 4(12):101307. PubMed ID: 38056464
[TBL] [Abstract][Full Text] [Related]
53. Generation of molecular-targeting helix-loop-helix peptides for inhibition of the interaction between cytotoxic T-lymphocyte-associated protein 4 and B7 in the dog.
Ramanayake Mudiyanselage TM; Fujiwara D; Michigami M; Watanabe S; Ye Z; Ueda A; Kanegi R; Hatoya S; Fujii I; Sugiura K
J Vet Med Sci; 2022 Aug; 84(8):1101-1107. PubMed ID: 35753760
[TBL] [Abstract][Full Text] [Related]
54. Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell-based immunotherapy.
Wijesekera DPH; Yuba E; De Silva NH; Watanabe SI; Tsukamoto M; Ichida C; Izawa T; Itoh K; Kanegi R; Hatoya S; Yamate J; Inaba T; Sugiura K
FASEB Bioadv; 2020 Jan; 2(1):5-17. PubMed ID: 32123853
[TBL] [Abstract][Full Text] [Related]
55. Canine Cancer: Strategies in Experimental Therapeutics.
Thamm DH
Front Oncol; 2019; 9():1257. PubMed ID: 31803625
[TBL] [Abstract][Full Text] [Related]
56. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma.
Konduri V; Halpert MM; Baig YC; Coronado R; Rodgers JR; Levitt JM; Cerroni B; Piscoya S; Wilson N; DiBernardi L; Omarbekov Z; Seelhoff L; Ravi V; Douglass L; Decker WK
Cancer Gene Ther; 2019 Sep; 26(9-10):282-291. PubMed ID: 30670791
[TBL] [Abstract][Full Text] [Related]
57. Innate immunity mediated by dendritic cells/macrophages plays a central role in the early period in tumor treatment using gene of Mycobacterium tuberculosis antigen.
Ushigusa T; Koyama Y; Ito T; Watanabe K; Chambers JK; Hasegawa A; Uchida K; Kanegi R; Hatoya S; Inaba T; Sugiura K
J Vet Med Sci; 2018 Feb; 80(2):190-196. PubMed ID: 29311492
[TBL] [Abstract][Full Text] [Related]
58. Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand.
De Silva NH; Akazawa T; Wijewardana V; Inoue N; Oyamada M; Ohta A; Tachibana Y; Wijesekera DPH; Kuwamura M; Nishizawa Y; Itoh K; Izawa T; Hatoya S; Hasegawa T; Yamate J; Inaba T; Sugiura K
PLoS One; 2017; 12(11):e0188738. PubMed ID: 29190690
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
